Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ · Health Care · market cap 113.59B

Share price

$516.34

At the last nightly close

Intrinsic value

$209.79

A single conservative estimate.

Margin of safety

-59.4%

($209.79 − $516.34) ÷ $516.34

EV / EBIT

1056.1

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earnings30.0
Price / book6.5
EV / EBITDA24.4
FCF / EV+0.6%
Return on equity+23.5%
Return on assets+11.9%
Debt / equity0.10
Gross margin+55.0%

Market position

52-week high$557.96
52-week low$376.62
From 52-week high-7.5%
RSI (14)45.3
200-day moving average$470.94

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY12.00B4.55B3.95B15.463.19B
2024-FY11.02B-233.4M-535.6M-2.08-978.0M
2023-FY9.87B3.78B3.62B14.053.28B
2022-FY8.93B4.25B3.32B12.973.93B
2021-FY7.57B2.78B2.34B9.012.41B

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 2, 2026
Consensus EPS estimate-1.74

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on VRTX.

Run the board on VRTX

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.